Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577405 | 1.00 | LMNA (0.49) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL9381103 | 0.88 | LMNA (0.50) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL6664480 | 0.88 | LMNA (0.53) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL14065374 | 0.84 | LMNA (0.47) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL10917684 | 0.83 | ALDH1A1 (0.40) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL11028522 | 0.83 | ALDH1A1 (0.55) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL3816217 | 0.82 | METTL3 (0.44) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL29548224 | 0.82 | DRD3 (0.63) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL3809668 | 0.82 | DRD3 (0.63) | LMNAALDH1A1DRD3KMT2AMEN1 | |
| SCHEMBL6212035 | 0.82 | TOP1 (0.41) | LMNAALDH1A1DRD3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| EP-3983078-B1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2023-11-15 | — | — | EP | disclosed |
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-08-11 | — | — | US | disclosed |
| EP-3983078-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950473-A | Next generation modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2020249773-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2020-12-17 | — | — | WO | disclosed |
| EP-0831845-B1 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | ELIZANOR BIOPHARMACEUTICALS IN (US) | 2004-09-08 | — | — | EP | disclosed |
| US-5854227-A | Therapeutic derivatives of diphosphonates | ELIZANOR BIOPHARMACUETICALS, INC. | 1998-12-29 | — | — | US | disclosed |
| WO-1996040156-A1 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | ELIZANOR BIOPHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4448962-A | BACTERICIDES | KYORIN SEIYAKU KABUSHIKI KAISHA | 1984-05-15 | — | — | US | disclosed |
| US-4292317-A | BACTERICIDES FOR GRAM NEGATIVE AND -POSITIVE BACTERIA; ANIMAL GROWTH REGULATORS | LABORATORIE ROGER BELLON (FR) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | LMNA 3293/4885ALDH1A1 4562/4885DRD3 3434/4885 |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | LMNA 3293/4885ALDH1A1 4562/4885DRD3 3434/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | LMNA 3293/4885ALDH1A1 4562/4885DRD3 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.